8-K: Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Obstructive Sleep Apnea

Mineralys Therapeutics has received FDA clearance for a Phase 2 clinical trial of lorundrostat to treat obstructive sleep apnea in patients with hypertension.

Summary

• Mineralys Therapeutics has announced that the FDA has cleared their Investigational New Drug (IND) application for a Phase 2 clinical trial of lorundrostat.
• The trial will evaluate the effect of lorundrostat in treating moderate-to-severe obstructive sleep apnea (OSA) in patients with hypertension.
• The company anticipates initiating the trial in the first quarter of 2025.
• The study will be a placebo-controlled, crossover study involving approximately 40 subjects at 40 sites.
• The primary outcome measure is the change in the frequency of apnea-hypopnea episodes.
• A key secondary objective is to quantify blood pressure throughout the night using continuous BP monitoring.
• The company believes its current cash will be sufficient to fund planned clinical trials and operations through the first quarter of 2026.
• Lorundrostat is a selective aldosterone synthase inhibitor being developed for hypertension, chronic kidney disease, and now OSA.

Sentiment

Score: 7

Explanation: The document is positive due to the FDA clearance and the initiation of a new clinical trial, but there are also significant risks and uncertainties associated with drug development.

Positives

• FDA clearance of the IND application allows Mineralys to proceed with a Phase 2 trial for lorundrostat in OSA.
• The trial design incorporates state-of-the-art technology and expertise in sleep medicine.
• The company has sufficient cash to fund operations through the first quarter of 2026.
• Lorundrostat has shown promising results in previous trials, including a 70% reduction in plasma aldosterone concentration.
• The trial will assess both the severity of upper airway obstruction and nocturnal hypertension.

Negatives

• The company's future performance is entirely dependent on the success of lorundrostat.
• There are potential risks of delays in the commencement, enrollment, and completion of clinical trials.
• The FDA may not approve the proposed pivotal program for lorundrostat.
• The company relies on third parties for manufacturing, research, and clinical testing.
• There is a risk of unexpected adverse side effects or inadequate efficacy of lorundrostat.
• Prior trial results are not necessarily predictive of future results.

Risks

• The company's success is heavily reliant on the success of lorundrostat.
• Clinical trials may face delays in commencement, enrollment, or completion.
• The FDA may not approve the proposed pivotal program for lorundrostat.
• The company depends on third parties for manufacturing and testing.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat could hinder development.
• Prior trial results may not predict future outcomes.
• Regulatory developments in the US and foreign countries could impact the company.
• The company relies on an exclusive license with Mitsubishi Tanabe Pharma for lorundrostat.

Future Outlook

The company plans to initiate a Phase 2 clinical trial for lorundrostat in obstructive sleep apnea in the first quarter of 2025 and believes its current cash will fund operations through the first quarter of 2026. The company is also exploring lorundrostat for other conditions such as chronic kidney disease and uncontrolled hypertension.

Management Comments

• Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, stated that the OSA program aligns with their strategy to develop lorundrostat in conditions driven by dysregulated aldosterone.
• Reena Mehra, MD, MS, a sleep disorders researcher and physician, stated that the OSA trial was designed in collaboration with thought leaders to ensure high-quality data.

Industry Context

This announcement is significant as it expands the potential market for lorundrostat into obstructive sleep apnea, a condition often comorbid with hypertension. This aligns with the broader industry trend of targeting specific disease drivers and developing precision medicines.

Comparison to Industry Standards

• The trial design, incorporating continuous blood pressure monitoring and sleep studies, aligns with industry best practices for OSA research.
• The focus on aldosterone-driven diseases is a targeted approach, differentiating Mineralys from companies pursuing broader hypertension treatments.
• The 70% reduction in plasma aldosterone concentration observed in previous trials is a strong indicator of lorundrostat's potential efficacy, comparing favorably to other aldosterone inhibitors in development.
• The company's approach to targeting OSA in hypertensive patients is a novel approach, as many companies focus on either hypertension or OSA separately.

Stakeholder Impact

• Shareholders will likely view the FDA clearance positively, potentially increasing the company's valuation.
• Patients with OSA and hypertension may benefit from a new treatment option if lorundrostat proves effective.
• Employees of Mineralys will be involved in the execution of the clinical trial.
• The company's suppliers and research partners will be involved in the trial.

Next Steps

• Initiate the Phase 2 clinical trial for lorundrostat in obstructive sleep apnea in the first quarter of 2025.
• Enroll approximately 40 subjects in the Phase 2 trial across 40 sites.
• Continue development of lorundrostat for other indications such as chronic kidney disease and uncontrolled hypertension.

Key Dates

Keywords

lorundrostat, obstructive sleep apnea, hypertension, clinical trial, FDA, aldosterone, Phase 2, cardiovascular, drug development, Mineralys Therapeutics